Repository logo

Browsing by Author "Dean, Gregg, advisor"

Now showing 1 - 6 of 6
  • Thumbnail Image
    ItemOpen Access
    Development of Lactobacillus acidophilus as an oral vaccine vector and effects of rice bran ingestion on the mucosal health of Malian infants
    (Colorado State University. Libraries, 2020) Vilander, Allison C., author; Dean, Gregg, advisor; Abdo, Zaid, committee member; Dow, Steven, committee member; MacNeill, Amy, committee member; Ryan, Elizabeth, committee member
    Most pathogens enter the body at the mucosa and induce innate and adaptive immune responses at these surfaces essential for protection against infection and disease. Induction of mucosal immune responses is best achieved locally but mucosal vaccines have been difficult to develop with few currently approved for use. Almost all are attenuated live vaccines which limits their use and efficacy in some populations. Strategies to enhance the mucosal immune response to vaccination and move away from attenuated live vaccines are needed. Prebiotics (nondigestible food ingredients that promotes growth of beneficial microorganisms) and probiotics (live microorganisms that are beneficial when ingested) are an active area of interest for improving mucosal health and increasing oral vaccine performance. Here we present the development of the probiotic Gram-positive lactic acid bacteria Lactobacillus acidophilus (LA) as a novel oral subunit vaccine. LA has many advantages as an oral vaccine vector including endogenous acid and bile resistance, heat tolerance, and numerous proteins that interact with the mucosal immune system. We show that LA can induce immune responses to weakly immunogenic neutralizing peptides from HIV-1 and rotavirus. To enhance the immune response, we developed the E. coli type I pilus protein, FimH, as a LA vaccine adjuvant. FimH increased the immune response to vaccination and increased LA trafficking by antigen presenting cells to the mesenteric lymph node, an important site of mucosal immune induction. We also evaluate the effects of ingestion of the nutrient dense prebiotic rice bran on mucosal health in a cohort of healthy Malian infants at risk for malnutrition and the subclinical condition environmental enteric dysfunction. Rice bran ingestion was found to decrease episodes of diarrhea, decrease the age to elevated fecal microbiome α-diversity, and stabilize total fecal secretory IgA concentrations over time. These results indicate that rice bran protects from diarrhea and improves the mucosal environment.
  • Thumbnail Image
    ItemOpen Access
    HIV prophylaxis: an essential role for T cells and adjuvants in recombinant mucosal Lactobacillus acidophilus vaccines
    (Colorado State University. Libraries, 2016) LeCureux, Jonathan Spicer, author; Dean, Gregg, advisor; Aboellail, Tawfik, committee member; Chen, Chaoping, committee member; Zabel, Mark, committee member
    Current HIV vaccines have poor efficacy, with inconsistent levels of protection following mucosal HIV exposure. Lactic acid bacteria offer an alternative vaccine vector targeting the primary site of HIV infection, the mucosa. In these studies we evaluated the immunogenicity of several strains of Lactobacillus acidophilus expressing HIV membrane proximal external region (MPER), a portion of HIV envelope that contains broadly neutralizing antibody binding sites. We evaluated MPER-only expressing strains along with strains expressing adjuvants (interleukin-1β or flagellin) to improve immunogenicity against the HIV MPER. We compared the adjuvant strains to the MPER-only strain by oral administration in BALB/c mice to observe these improvements, and in CD40L-/- mice to observe if T cell help was necessary. Some BALB/c animals were also placed on a modified diet supplemented with prebiotic rice bran to observe any influence on vaccine immunogenicity. Resulting antibody responses and interleukin-17 levels were measured by ELISA, and T and B cell levels were measured by flow cytometry. Here we show that the addition of adjuvants, including dietary rice bran, to L. acidophilus vaccine strains improves their immunogenicity against HIV MPER. Our results indicate that anti-MPER IgG and IgA levels, as well as the number of anti-MPER antibody secreting cells, are improved with adjuvants, and that T cell help is required for an effective immune response. These results, combined with the many advantages offered by this lactic acid bacteria vaccine system make L. acidophilus an attractive vaccine vector for primate and human trials.
  • Thumbnail Image
    ItemOpen Access
    Microbes in the mucosa: impacts of the mucosal immune system and oral vaccination with Lactobacillus acidophilus on the gut microbiome
    (Colorado State University. Libraries, 2021) Fox, Bridget E., author; Dean, Gregg, advisor; Abdo, Zaid, advisor; Tobet, Stuart, committee member; Ryan, Elizabeth, committee member
    The mucosal immune system is constantly balancing between the clearance of pathogens, tolerance of self-antigen and food, and maintenance of homeostasis within the microbiota. Vaccination via mucosal routes is advantageous because it provides protection at local mucosal sites and systemically. However, induction of efficacious responses are often difficult due to the inherent barriers of the mucosal tissues. We have developed a probiotic-based mucosal vaccination platform that utilizes recombinant Lactobacillus acidophilus (rLA) to overcome these obstacles presented in oral vaccination. Here, we sought to determine whether repeated administration of rLA alters the intestinal microbiome as a result of L. acidophilus probiotic activity (direct competition and selective exclusion) or from the host's mucosal immune response against the rLA vaccine. To address the latter, IgA-seq was employed to characterize shifts in IgA-bound bacterial populations. Additionally, we determined whether using rice bran as a prebiotic would influence the immunogenicity of the vaccine and/or IgA bound bacterial populations. Our results show that the prebiotic influenced the kinetics of rLA antibody induction, and that the rLA platform does not cause lasting disturbances to the microbiome. Nucleotide-binding oligomerization domain containing 2 (NOD2) has presented itself as an essential regulator of immune responses within the gastrointestinal tract. This innate immune receptor is expressed by several cell types, including both hematopoietic and nonhematopoietic cells within the gastrointestinal tract. Mice harboring knockouts of NOD2 only in CD11c+ cells were used to better characterize NOD2 signaling during mucosal vaccination with rLA. We show that NOD2 signaling in CD11c+ cells is critical for mounting a humoral immune response against rLA. Additionally, disruption of NOD2 signaling in CD11c+ cells results in an altered bacterial microbiome profile in both vaccinated and unvaccinated mice.
  • Thumbnail Image
    ItemOpen Access
    Mucosal and systemic immune correlates of protection against feline enteric coronavirus infection
    (Colorado State University. Libraries, 2019) Pearson, Morgan, author; Dean, Gregg, advisor; Schountz, Tony, committee member; Webb, Craig, committee member; Avery, Anne, committee member
    Feline infectious peritonitis (FIP) is a disease with high mortality that results from a mutation in the genome of the relatively harmless and ubiquitous feline coronavirus (FCoV) (Licitra, Millet et al. 2013). FIP causes a deadly effusive and/or granulomatous disease in cats (Kipar, May et al. 2005). Because FIP is always fatal, our aim is to aid with the development of a vaccine against the parent virus FCoV. The goal of this study is to complete a comprehensive assessment of the mucosal immune response associated with FCoV infection and clearance. Previous research has shown that cats infected with FCoV can clear the virus, or they can become intermittent or persistent virus shedders (Marks 2016). It is thought that rapid waning of the humoral immune response predisposes cats to reinfection (Myrrha, Silva et al. 2011). A closed cat colony with circulating FCoV infection was studied longitudinally to assess mucosal immune correlates of protection. Blood and fecal samples were collected monthly and colonic biopsies were obtained at an arbitrary time 0. Virologic assessment included PCR detection of virus in feces and colonic tissue. Immunological assessment included FECV-specific serum IgG and fecal IgA. Lamina propria lymphocytes from colon biopsies were phenotyped using flow cytometry and were assessed for FCoV-specific IgA and IFNγ expression by ELISPOT. Expression of IL17 and FoxP3 was measured by qRT-PCR. Although histopathology of colonic biopsies from cats shedding virus was unremarkable, an inflammatory state was indicated by total IgA producing cells, IFNγ production, and increased IL17:FoxP3. FCoV-specific IgA was also associated with viral shedding. Taken together, results indicate mucosal and systemic antibody responses are responsible for limiting FECV infection while cell-mediated responses were not detected. Therefore, a vaccine strategy targeting antibody induction via a mucosal route may provide protection against FECV infection.
  • Thumbnail Image
    ItemEmbargo
    Of microbes and mothers: evaluating the complex maternal-neonatal interaction and microbiome-immunity development with novel Lactobacillus vaccination
    (Colorado State University. Libraries, 2024) Ecton, Kayl E., author; Abdo, Zaid, advisor; Dean, Gregg, advisor; Wrighton, Kelly, committee member; Vilander, Allison, committee member; Argueso, Lucas, committee member
    The task of identifying an optimal vaccination strategy for neonates has been challenging scientists and physicians alike. Multiple factors contribute to the difficulty in establishing an optimal platform including the complexity of the maternal-fetal dyad, a neonatal Th2 skewed profile and the role of the parallel development of the immune system and the gut microbiome (8). Disease remains a main cause of infant morbidity and mortality, encouraging the discovery of novel infant vaccinations to be delivered during the first 28 days of life to provide protection (41). Passive protection from the maternal transfer of transplacental IgG and both IgG and IgA in breastmilk has a limited window of operation, leaving the maturing neonate at risk (128). Although exact mechanisms remain to be elucidated, here we examine the complex crosstalk between mother-fetus and maternal-neonate dyads, neonatal microbiome-immunity development, and optimal delivery strategies for neonatal vaccine development. In this dissertation we investigated the role of maternal infection prior to gestation, neonatal challenge after vaccination, and vaccine effectiveness after exposure to virus. We evaluated the use of a novel vaccine platform developed previously in the lab as an orally delivered mucosal targeting subunit vaccine in Lactobacillus acidophilus. We investigated the effectiveness of the recombinant vaccine with and without adjuvants in a neonatal experimental design model and discovered increased virus specific responses in neonates vaccinated with adjuvants when challenged with rotavirus. We show a significant impact of maternal influence on neonatal outcomes. Beyond the immunogenic strength of the novel Lactobacillus acidophilus vaccine platform in neonates, we identified induced shifts to the gut microbial communities that occurred with vaccination or infection. We saw a shift in the gut microbiome over the course of a 7-day rotavirus challenge in neonates that did not return to baseline during the observation period, even after no virus shedding was detected in fecal samples. We also evaluated the impact of different doses, 1x106 CFU/dose and 1x109 CFU/dose, on the immune response and the gut microbiome. We confirmed the role of fecal microbiome transplants in breeding does to normalize for the maternal microbiome prior to gestation. Our results indicate that there are modifications to the gut microbiome and changes in immune antibodies during vaccination and infection. While we did not pursue a specific mechanism crosslinking the maternal-neonatal interaction and the gut-immunity relationship, we do consider the presence of such a connection.
  • Thumbnail Image
    ItemEmbargo
    The adventures of Lactobacillus acidophilus: evaluating a recombinant probiotic rotavirus vaccine from host and microbial perspectives
    (Colorado State University. Libraries, 2024) Gilfillan, Darby L., author; Vilander, Allison, advisor; Dean, Gregg, advisor; Abdo, Zaid, committee member; Wilkins, Mike, committee member
    Rotavirus is an enteric infection of global importance causing diarrheal-associated illness that can be fatal in young children and the elderly. There is a gap in vaccine efficacy between high- and lower-middle-income countries (LMIC) with LMIC often experiencing diminished vaccine-conferred protection. Rotaviruses, whether attenuated vaccine strains or primary pathogens, do not exist in isolation within the host's gastrointestinal tract. Other actors present within the microbiome can inhibit or augment vaccine efficacy by influencing the vaccine itself or the mucosal immune response. Understanding and exploiting interactions between host and microbe is a promising frontier for mucosal vaccinology. This dissertation will explore the probiotic Lactobacillus acidophilus (LA) as a vaccine platform for a microbiome-minded, next-generation approach to rotavirus immunization. We developed and confirmed a novel recombinant LA (rLA) vaccine expressing rotavirus antigens of the VP8* domain from the rotavirus EDIM VP4 capsid protein along with the adjuvants FimH and FliC. Rotavirus naïve adult BALB/cJ mice were orally immunized followed by murine rotavirus strain ECWT viral challenge. Antirotavirus serum IgG and antigen-specific antibody-secreting cell responses were detected in rLA-vaccinated mice. A day after the oral rotavirus challenge, fecal antigen shedding was significantly decreased in the rLA group. These results demonstrate the potential of rLA platforms to generate protective mucosal immunity. Additionally, metagenomic and metatranscriptomic analyses of exogenous probiotic administration within the murine small intestine revealed differences between LA genome expression and the whole metatranscriptome in recombinant- versus wild-type LA-vaccinated mice. LA genome expression in rLA-vaccinated mice had decreased carbohydrate metabolism and increased stress responses. We also detected antigen and adjuvant transcript expression only in mice exposed to the rLA platform. There was relative enrichment of probiotic species in the wild-type group with overall increased α- and β-diversity in the buffer compared to probiotic groups. These results highlight the interactions between an exogenous probiotic and the host microbiome at an immune inductive site. Finally, we used an in vitro model to evaluate modulation of polyunsaturated fatty acid (PUFA) metabolism on host cell and (r)LA interactions. Both (r)LA and PUFA treatments significantly changed pathogen recognition receptor expression. (r)LA treatment mainly altered inflammatory cytokine expression while PUFA supplementation primarily influenced mucin expression. rLA strains adhered more to host cells than wild-type LA while the rLA strain expressing both antigens and adjuvants may better prevent E. coli adhesion. These results and methodologies provide a starting point for further investigation into PUFA metabolism as a mechanism for improving rLA immunogenicity and competition against other enteric pathogens.